Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Zippia finds jobs where you're a top candidate and applies on your behalf.
| CEO | Philip Astley-Sparke |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 152 |
| Date Founded | 2015 |
| Headquarters | Woburn, Massachusetts |
| Revenue | $296.4M |
| Net Income | -$174,284,000 |
| Tax Rate | -0.0% |
| Total Assets | $646,591,000 |
| Ticker | REPL |
Replimune received early financing of $2.0M on 2015-05-08.
| Series | Round size | Date |
|---|---|---|
| Seed | $2M | 05/2015 |
| Series A | $30M | 09/2015 |
| Series B | $55M | 09/2017 |
| Investors | Security type |
|---|---|
| Forbion Capital Partners | Seed |
| Omega Funds | Seed |
| Forbion Capital Partners | Series A |
| Omega Funds | Series A |
| Atlas Venture | Series A |
| Redmile Group | Series B |
| Bain Capital Life Sciences | Series B |
| Forbion Capital Partners | Series B |
| Cormorant Asset Management | Series B |
| Omega Funds | Series B |
| Foresite Capital | Series B |
| Leerink Partners LLC | Series B |
| Atlas Venture | Series B |
Replimune's top competitor, eFFECTOR Therapeutics, earned an annual revenue of $42.0M.
Replimune's smallest competitor is Unleash Immuno Oncolytics with revenue of $94.0K last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Oncorus | - | $8.5M | 50 | - |
| eFFECTOR Therapeutics | - | $42.0M | 24 | - |
| Genocea | - | - | 59 | - |
| Western Oncolytics | - | $1.2M | 12 | - |
| Rheos Medicines | - | $1.2M | 46 | - |
| Pionyr Immunotherapeutics | - | $1.6M | 58 | - |
| Unleash Immuno Oncolytics | - | $94,000 | 1 | - |
Zippia gives an in-depth look into the details of Replimune, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Replimune. The employee data is based on information from people who have self-reported their past or current employments at Replimune. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Replimune. The data presented on this page does not represent the view of Replimune and its employees or that of Zippia.
Replimune may also be known as or be related to REPLIMUNE GROUP, INC., Replimune, Replimune Group Inc, Replimune Group Inc. and Replimune Group, Inc.